Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15;38(14):1987-1990.
doi: 10.1097/QAD.0000000000004010. Epub 2024 Oct 31.

Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV

Matteo Augello  1 , Valeria Bono, Roberta Rovito, Andrea Santoro, Camilla Tincati, Giulia Marchetti
Affiliations

Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV

Matteo Augello et al. AIDS. .

Abstract

In this prospective longitudinal study, we evaluated the durability of humoral responses to SARS-CoV-2 mRNA booster vaccination in 93 people with HIV, exploring the possible role of T-cell dysfunction and inflammaging biomarkers in predicting antibody waning. We found that, despite a negligible influence of the inflammaging milieu, low CD4/CD8 ratio and CD4+CD127+ percentage as well as high CD8+CD38+CD45RO+ percentage are associated with faster antibody waning, in turn contributing to our understanding of the determinants of COVID-19 vaccine-elicited immune response in this population.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflicts of interest related to this work to disclose.

Figures

Fig. 1
Fig. 1
Anti-S IgG antibodies concentrations and associations with markers of T-cell dysfunction and inflammaging.
See this image and copyright information in PMC

References

    1. Augello M, Bono V, Rovito R, Tincati C, Marchetti G. Immunologic interplay between HIV/AIDS and COVID-19: adding fuel to the flames?. Curr HIV/AIDS Rep 2023; 20:51–75. - PMC - PubMed
    1. Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, et al. . Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network. Int J Infect Dis 2023; 136:127–135. - PubMed
    1. Peluso MJ, Antar AAR. Long COVID in people living with HIV. Curr Opin HIV AIDS 2023; 18:126–134. - PMC - PubMed
    1. Martín-Iguacel R, Moreno-Fornés S, Bruguera A, Aceitón J, Nomah DK, González-Cordón A, et al. . Major cardiovascular events after COVID-19 in people with HIV. Clin Microbiol Infect 2024; 30:674–681. - PubMed
    1. Augello M, Bono V, Rovito R, Tincati C, d’Arminio Monforte A, Marchetti G. Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection. AIDS 2023; 37:1503–1517. - PMC - PubMed